Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...
A normative computational model of individual differences in mouse exploration driven by reward and threat uncertainty as well as risk sensitivity when faced with a novel object in an open field.
Researchers have used metamathematical techniques to show that certain theorems that look superficially distinct are in fact ...
The University of Pennsylvania and Vanderbilt are revamping business education as AI transforms Wall Street.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback